CryoLife Reports Record Quarterly Revenues of $28...(ard in time or that express management's...),Health

Date:7/30/2009

ard in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated 2009 performance and our growth prospects and statements regarding the expected impact of our net operating loss carryforwards on our cash outlays for tax obligations. These future events may not occur as and when expected, if at all, and, together with our business, are subject to various risks and uncertainties. These risks and uncertainties include that we are significantly dependent on revenues from BioGlue and there are a variety of risks affecting BioGlue, CryoValve SG pulmonary heart valves and other SynerGraft processed tissues and products may not be accepted by the marketplace, the CryoValve SG pulmonary heart valve has a one year shelf life, we are dependent on the availability of sufficient quantities of tissue from human donors, the CryoValve SG pulmonary heart valve post-clearance study requested by the FDA may not provide the expected positive results, our products and tissues we process and preserve have allegedly caused and may in the future cause injury to patients, and we have been and may be exposed to tissue processing and product liability claims and additional regulatory scrutiny as a result, the possibility that the FDA could impose additional restrictions on the Company's operations, issue a 483, or warning letter, or require a recall, or prevent the Company from processing and distributing tissues or manufacturing and distributing other products, our failure to adequately comply with government regulations could result in loss of revenues and customers as well as additional compliance expense, our ability to borrow under our credit facility may be limited, the credit facility limits our ability to pursue significant acquisitions, the financial and credit liquidity crisis may adversely affect our ability to bor
'/>"/>

SOURCE CryoLife, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. CryoLife Announces Release Date and Teleconference Call Details for 2009 Second Quarter Financial Results
2. Department of Defense Awards CryoLife $1.7 million to Develop BioFoam Hemostatic Technology
3. CryoLife Announces Release Date and Teleconference Call Details for First Quarter 2008 Financial Results
4. William F. Northrup, III, M.D. Joins CryoLife as Vice President of Medical Relations and Education
5. Cryolife Victim Responds to Untrue Assertions of Cryolife
6. CryoLife Announces Additions to Management Team
7. Gentiva Reports Second Quarter 2009 Results
8. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
9. Encision Reports Profitable First Fiscal Quarter Results
10. Nutraceutical Reports Fiscal 2009 Q3 Results and Expands Share Repurchase Program
11. Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share